Tandem Diabetes Care integrates insulin pump with Abbott’s FreeStyle Libre 3 Plus CGM sensor

Tandem Diabetes Care insulin pump integrates with FreeStyle Libre 3: ©Pixelshot

Tandem Diabetes Care Inc. announced that its t:slim X2 insulin pump with Control-IQ+ technology now integrates with Abbott’s FreeStyle Libre 3 Plus continuous glucose monitoring (CGM) sensor, marking a major step forward in personalized diabetes management.

The integration allows users of the FreeStyle Libre 3 Plus sensor—capable of delivering glucose readings every minute for up to 15 days—to share real-time data directly with the t:slim X2 pump. This seamless data connection enables more precise insulin adjustments every five minutes using Tandem’s Control-IQ+ algorithm, which includes the company’s unique AutoBolus feature.

“This is an exciting first step in our strategy to connect Tandem's portfolio of insulin pumps to Abbott’s FreeStyle Libre 3 Plus sensors worldwide,” said John Sheridan, president and CEO of Tandem Diabetes Care.

The company has launched an early access program in the U.S. and plans to expand availability in the second half of 2025. The integration will also allow glucose data to be viewed through the t:slim mobile app, providing multiple ways for users to track their glucose trends.

“Diabetes management is not one-size-fits-all and it is critical for people living with diabetes to be able to personalize their AID systems,” said Jordan Pinsker, chief medical officer of Tandem Diabetes Care. “This integration… allows even more CGM users to access the life-changing benefits of our Control-IQ+ technology.”

Advances in diabetes technology continue to empower patients

The integration of insulin pumps with continuous glucose monitors represents one of the most transformative trends in diabetes care today. Automated insulin delivery (AID) systems, often referred to as hybrid closed-loop systems, are increasingly recommended by major medical organizations, including the American Diabetes Association, as the standard of care for individuals with type 1 diabetes and others requiring intensive insulin therapy.

Recent innovations have focused on making these systems more user-friendly, accurate, and personalized.

Additionally, CGMs have evolved significantly. The Abbott FreeStyle Libre 3 Plus sensor, for instance, offers minute-by-minute data and longer wear times (15 days), with factory calibration that eliminates the need for fingerstick tests. Combined with mobile apps and cloud-based data sharing, these tools give patients and providers a clearer picture of glucose trends and variability.

As more device makers collaborate and systems become interoperable, patients are gaining greater flexibility to tailor technology to their lifestyles and health goals. In the coming years, experts anticipate further progress toward fully closed-loop systems requiring minimal user input—a development that promises to make diabetes management more automated and less burdensome than ever before.